BACK CALCULATED DATA AGREE WITH EXPERIMEN TAL NOESY SPECTRUM, STRUCTURES WITH ACCEPTABLE COVALENT GEOMETRY,STRUCTURES WITH FAVORABLE NON-BOND ENERGY,STRUCTURES WITH THE LEAST RESTRAINT VIOLATIONS,STRUCTURES WITH THE LOWEST ENERGY, TARGET FUNCTION
代表モデル
-
要素
#1: タンパク質
TATPROTEIN / TRANSACTIVATING REGULATORY PROTEIN
分子量: 9789.319 Da / 分子数: 1 / 由来タイプ: 合成 詳細: THIS PEPTIDE WAS SYNTHESIZED (SOLID PHASE SYNTHESIS). THE SEQUENCE OF THIS PEPTIDE OCCURS NATURALLY IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 参照: UniProt: P04610
-
実験情報
-
実験
実験
手法: 溶液NMR
NMR実験
Conditions-ID
Experiment-ID
Solution-ID
タイプ
1
1
1
2D TOCSY
1
2
1
2D NOESY
1
3
1
3D 13C-SEPARATED NOESY
-
試料調製
詳細
内容: SPECIFIC 13C LABELLING OF GLYCINE 15,44,48,61,79,83
試料状態
pH: 4.5 / 温度: 298.00 K
結晶化
*PLUS
手法: other / 詳細: NMR
-
NMR測定
NMRスペクトロメーター
タイプ: Bruker DRX / 製造業者: Bruker / モデル: DRX / 磁場強度: 500 MHz
-
解析
NMR software
名称
バージョン
開発者
分類
DISCOVER 95
97
MSI
精密化
Felix
95
構造決定
97 AND
98
構造決定
NMR_REFINE
97
構造決定
HOMOLOGY
95
構造決定
97
構造決定
98
構造決定
精密化
手法: SIMULATED ANNEALING, RANDOM LOOP RESEARCH VALIDATED WITH NOE BACK-CALCULATION ENERGY MINIMIZATION, MOLECULAR DYNAMIC ソフトェア番号: 1 詳細: THE STRUCTURES ARE BASED ON A TOTAL OF 915 RESTRAINTS AND 272 ARE LONG-RANGE NOES.
NMRアンサンブル
コンフォーマー選択の基準: BACK CALCULATED DATA AGREE WITH EXPERIMEN TAL NOESY SPECTRUM, STRUCTURES WITH ACCEPTABLE COVALENT GEOMETRY,STRUCTURES WITH FAVORABLE NON-BOND ENERGY,STRUCTURES ...コンフォーマー選択の基準: BACK CALCULATED DATA AGREE WITH EXPERIMEN TAL NOESY SPECTRUM, STRUCTURES WITH ACCEPTABLE COVALENT GEOMETRY,STRUCTURES WITH FAVORABLE NON-BOND ENERGY,STRUCTURES WITH THE LEAST RESTRAINT VIOLATIONS,STRUCTURES WITH THE LOWEST ENERGY, TARGET FUNCTION 計算したコンフォーマーの数: 100 / 登録したコンフォーマーの数: 11